Related Experiment Videos
[Filgrastim therapy in acute nonlymphoblastic leukemia]
Terapevticheskii Arkhiv
|February 24, 2001
Summary
Granulocytic colony-stimulating factor (G-CSF) speeds neutrophil recovery in acute myeloid leukemia (AML) patients, reducing fever and antibiotic use. This treatment helps overcome neutropenia and its complications effectively.
Area of Science:
- Hematology
- Oncology
Background:
- Acute myeloid leukemia (AML) treatment often leads to neutropenia, increasing infection risk.
- Granulocytic colony-stimulating factor (G-CSF) is a therapeutic agent used to stimulate neutrophil production.
Purpose of the Study:
- To evaluate the efficacy of G-CSF (filgrastim) in mitigating neutropenia during AML induction therapy.
- To assess the impact of G-CSF on recovery time, febrile periods, and antibiotic use in AML patients.
Main Methods:
- A cohort of 13 AML patients received standard induction chemotherapy (cytosine arabinoside + daunorubicin).
- G-CSF (filgrastim) was administered subcutaneously during the neutropenic phase until neutrophil recovery.
- A control group received the same chemotherapy without G-CSF.
Main Results:
- Patients treated with G-CSF showed a significantly faster recovery of neutrophil counts (12.6 vs 16.8 days).
- The G-CSF group experienced reduced febrile periods and shorter durations of parenteral antibiotic treatment.
- No significant difference in antimycotic treatment duration was observed; no disease aggravation was noted.
Conclusions:
- G-CSF administration is beneficial in AML treatment, accelerating neutrophil recovery.
- G-CSF effectively reduces complications associated with neutropenia, such as fever and infections.